INDs/NDAs/CTDs
March 09 - 11, 2009
Burlingame, CA
Online Registration is not available at this time. Click on the Notify Me button to the left to be notified when online registration is available.
This course is available as a client site course. Please click here for more information.
Who Should Attend
This course is directed to personnel involved in:
• New Pharmaceutical Product Development
• Pre-clinical and Clinical Research
• Regulatory Affairs
• Quality Assurance
Participants should have an understanding of the steps in new
product development and/or the responsibilities of regulatory
affairs in submitting new product applications worldwide.
Description
The content of this course is to present detailed components
of INDs/NDAs, BLAs, ANDAs, SNDAs, IMPDs and CTDs
(Modules 1–5). These regulatory submissions will be based
on the requirements of the US code of Federal Regulations,
EU Directives and ICH guidelines. Each of these regulatory
documents will be presented as they are related to safety,
quality and efficacy necessary for global submissions. Details
of non and pre-clinical data, clinical data, and CMC data
necessary to achieve new product approvals globally will be
presented and discussed. Recommendations for expediting
new product approvals will be correlated with the regulatory
procedures.
Other topics presented that will help participants understand
the structure and bureaucratic demands will include:
• FDAs internal structure, policies and procedures
• Regulation requirements for new product submissions
including SNDAs, CTDs and DMFs globally
• Acceptance of international data for use in new product
approvals
• Similarities between EU directives and FDAs Code of
Federal Regulations